{"entity":{"id":"nct06500884","kind":"trial","name":"A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events","aka":[],"tldr":"A phase 2 trial of Talquetamab in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.","summary":"A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events is a phase 2 interventional study registered as NCT06500884 by Janssen Research & Development, LLC, with 210 participants planned, started 2024-08-26 and due to reach its primary completion in 2030-05-30. Interventions recorded: Talquetamab, Prophylaxis A, Prophylaxis B, Prophylaxis C, Prophylaxis D. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06500884","url":"https://clinicaltrials.gov/study/NCT06500884"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["talquetamab"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06500884","phase":"2","setting":"A Phase 2, Open-label, Randomized Study to Evaluate GPRC5D-related Oral Events","sponsor":"Janssen Research & Development, LLC","enrolled":210,"outcomes":[]},"route":"/trials/nct06500884/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"talquetamab","kind":"drug","name":"Talquetamab","route":"/drugs/talquetamab/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}